On October 9, CANSINOBIO fell 5.34% in regular trading, trading at HK$34.02, pressured by a cross-market negative sentiment following a sharp selloff in US vaccine giant Moderna and a downgrade from Citi. The stock had rallied strongly during the National Day holiday on ESMO data expectations, creating significant short-term profit-taking pressure.

CANSINOBIO is a clinical-stage Chinese vaccine company. Its products include the Ebola virus vaccine Ad5-EBOV, meningococcal vaccines MCV2 and MCV4, pneumococcal vaccine PBPV, and a recombinant COVID-19 vaccine. Its products are mainly applied in the fields of meningitis, DTP, and pneumonia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)